Norio Ozaki, Fujita Health University School of Medicine, Toyoake, Japan
Published online: July 2006
DOI: 10.1038/npg.els.0005162
Pharmacogenetics is the science of pharmacological response and its modification by hereditary influence; psychopharmacogenetics is the application of pharmacogenetics to the field of psychiatry.
Keywords: psychopharmacology; polymorphism; pharmacokinetics; pharmacodynamics; pharmacogenomics
| References | |
| Arranz MJ, Munro J, Birkett J, et al. (2000) Pharmacogenetic prediction of clozapine response. The Lancet 355: 1615–1616. | |
| Detera-Wadleigh SD (2001) Lithium-related genetics of bipolar disorder. Annals of Medicine 33: 272–285. | |
| Kawanishi Y, Tachikawa H and Suzuki T (2000) Pharmacogenomics and schizophrenia. European Journal of Pharmacology 410: 227–241. | |
| Lin KM (2001) Biological differences in depression and anxiety across races and ethnic groups. Journal of Clinical Psychiatry 62: 13–19. | |
| Masellis M, Basile VS, Ozdemir V, et al. (2000) Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biological Psychiatry 47: 252–266. | |
| Pickar D and Rubinow K (2001) Pharmacogenomics of psychiatric disorders. Trends in Pharmacological Sciences 22: 75–83. | |
| Pirmohamed M and Park BK (2001) Genetic susceptibility to adverse drug reactions. Trends in Pharmacological Sciences 22: 298–305. | |
| Scharfetter J (2001) Dopamine receptor polymorphisms and drug response in schizophrenia. Pharmacogenomics 2: 251–261. | |
| Weizman A and Weizman R (2000) Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics 1: 335–341. | |
| Wong ML and Licinio J (2001) Research and treatment approaches to depression. Nature Reviews Neuroscience 2: 343–351. | |
| Further Reading | |
| Bader JS (2001) The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics 2: 11–24. | |
| Cargill M and Daley GQ (2000) Mining for SNPs: putting the common variants–common disease hypothesis to the test. Pharmacogenomics 1: 27–37. | |
| Harris S and Foord SM (2000) Transgenic gene knock-outs: functional genomics and therapeutic target selection. Pharmacogenomics 1: 433–443. | |
| Ingelman-Sundberg M (2001) Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine 250: 186–200. | |
| Martinez D, Broft A and Laruelle M (2001) Imaging neurochemical endophenotypes: promises and pitfalls. Pharmacogenomics 2: 223–237. | |
| Phillips KA, Veenstra DL, Oren E, Lee JK and Sadee W (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. Journal of the American Medical Association 286: 2270–2279. | |
| Roses AD (2002) Pharmacogenetics place in modern medical science and practice. Life Sciences 70: 1471–1480. | |
| Rothstein MA and Epps PG (2001) Ethical and legal implications of pharmacogenomics. Nature Reviews Genetics 2: 228–231. | |
| Steimer W and Potter JM (2002) Pharmacogenetic screening and therapeutic drugs. Clinica Chimica Acta 315: 137–155. | |
| Wang X and Feuerstein GZ (2000) Suppression subtractive hybridisation: application in the discovery of novel pharmacological targets. Pharmacogenomics 1: 101–108. | |
Copyright © 2000-2013 by John Wiley & Sons, Inc., or related companies. All rights reserved.
